CRIS Current Research Information System

DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.115
NA - Nord America 1.946
EU - Europa 1.301
SA - Sud America 200
AF - Africa 154
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.724
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.897
VN - Vietnam 1.177
SG - Singapore 1.135
CN - Cina 850
HK - Hong Kong 500
DE - Germania 325
IT - Italia 267
BR - Brasile 136
KR - Corea 136
FR - Francia 124
NL - Olanda 115
SE - Svezia 107
FI - Finlandia 78
IN - India 75
GB - Regno Unito 72
JP - Giappone 51
CI - Costa d'Avorio 46
IE - Irlanda 44
SC - Seychelles 40
RU - Federazione Russa 38
PH - Filippine 34
ID - Indonesia 30
BD - Bangladesh 26
CA - Canada 22
PL - Polonia 22
TH - Thailandia 22
AR - Argentina 21
TG - Togo 18
AT - Austria 17
BG - Bulgaria 17
MX - Messico 17
BE - Belgio 16
CO - Colombia 13
ES - Italia 12
GH - Ghana 12
TW - Taiwan 11
ZA - Sudafrica 11
IQ - Iraq 10
CH - Svizzera 9
TR - Turchia 9
CL - Cile 8
EC - Ecuador 8
JO - Giordania 8
VE - Venezuela 8
AU - Australia 7
GR - Grecia 6
LT - Lituania 6
PK - Pakistan 6
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 4
KE - Kenya 4
MA - Marocco 4
MY - Malesia 4
NP - Nepal 4
SA - Arabia Saudita 4
TN - Tunisia 4
AL - Albania 3
EG - Egitto 3
JM - Giamaica 3
PY - Paraguay 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MU - Mauritius 2
NG - Nigeria 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AO - Angola 1
BY - Bielorussia 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KW - Kuwait 1
LU - Lussemburgo 1
LY - Libia 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 7.724
Salva come PNG Salva come JPEG
Città #
Singapore 850
Hong Kong 446
San Jose 392
Ho Chi Minh City 316
Hanoi 312
Hefei 299
Ashburn 274
Santa Clara 157
Los Angeles 136
Seoul 128
Council Bluffs 100
Chandler 96
Beijing 79
Boardman 65
Da Nang 59
Bologna 58
Lauterbourg 58
Helsinki 53
Abidjan 46
Dublin 43
Haiphong 42
Krefeld 41
Dallas 39
Buffalo 37
Southend 37
Tokyo 36
New York 34
Munich 33
Amsterdam 31
Frankfurt am Main 31
Princeton 28
Bengaluru 27
Fairfield 27
Falkenstein 26
Milan 23
Shanghai 23
Lappeenranta 22
Jakarta 19
Lomé 18
Redondo Beach 18
Nuremberg 17
Rome 17
Sofia 17
Chicago 16
Guangzhou 16
Hải Dương 16
Seattle 16
Bad Bellingen 15
Shenzhen 14
Brussels 13
Warsaw 13
Des Moines 12
Houston 12
São Paulo 12
Wilmington 12
Accra 11
Cambridge 11
Turin 11
Woodbridge 11
Bangkok 10
Berlin 10
Düsseldorf 10
Brooklyn 9
London 9
Ninh Bình 9
Rio de Janeiro 9
Thái Nguyên 9
Tongling 9
Amman 8
Bắc Ninh 8
Can Tho 8
Mexico City 8
Orem 8
San Diego 8
San Francisco 8
Biên Hòa 7
Bắc Giang 7
Ha Long 7
Hangzhou 7
Nha Trang 7
Stockholm 7
Ann Arbor 6
Bexley 6
Bến Tre 6
Fort Worth 6
Genoa 6
Hillsboro 6
Montreal 6
Monzuno 6
Moscow 6
Nanjing 6
Quận Bình Thạnh 6
Toronto 6
Trento 6
Điện Bàn 6
Bern 5
Cao Lanh 5
Castel Maggiore 5
Denver 5
Harbin 5
Totale 5.112
Salva come PNG Salva come JPEG
Nome #
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 279
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 205
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 188
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 181
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 178
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 174
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients 169
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 166
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 164
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome 153
Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications 151
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 150
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 148
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 147
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 144
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 143
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 140
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. 138
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 128
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 124
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 119
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 118
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 116
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 116
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 112
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 110
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 110
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 102
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer 101
CAR-T cell therapy: A potential new strategy against prostate cancer 100
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 95
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 94
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 94
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) 92
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 92
New prognostic biomarkers in metastatic castration-resistant prostate cancer 91
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 88
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 86
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 85
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 83
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy 82
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 82
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 79
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics 79
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial 77
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 76
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 75
Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers 75
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 74
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 73
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 73
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors 72
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 70
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 68
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer 68
Immunotherapy for prostate cancer: Where we are headed 65
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 63
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma 61
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 60
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 57
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 57
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 56
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 56
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 55
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 54
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 54
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 53
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 52
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 51
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer 51
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 50
Bevacizumab as maintenance treatment in patients with ovarian cancer: Wait for BRCA testing 48
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 46
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA 46
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 42
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer Patients 40
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 40
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients 37
Psychosocial issues in long-term survivors of testicular cancer 35
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 34
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 31
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 28
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 28
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 24
Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900] (Critical Reviews in Oncology / Hematology (2023) 181, (S1040842822003249), (10.1016/j.critrevonc.2022.103900)) 24
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 21
Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404](S1040842824001471)(10.1016/j.critrevonc.2024.104404) 18
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 15
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors 13
Therapeutic challenges for cisplatin-resistant ovarian germ cell tumors 13
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review 13
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 11
Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3) 8
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors 8
null 2
Totale 7.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.537
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.537
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 0 0 1 22
2021/2022234 4 0 3 6 9 4 25 16 5 50 74 38
2022/2023343 20 48 11 47 22 44 8 16 72 9 20 26
2023/2024364 10 17 5 3 9 39 15 15 204 21 17 9
2024/20251.699 100 207 121 152 230 108 52 68 17 138 101 405
2025/20265.142 357 423 386 363 452 117 1.238 347 1.044 415 0 0
Totale 7.917